Zurich, March 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD). Ypsomed is supporting a reliable transition to ensure the supply of pen needles to people around the globe who inject insulin and other hormones. During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23 and CHF 18 million in the first half of FY 2023/24. The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary respectively regulatory conditions. Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in busi­ness-to-busi­ness operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide. CMS ZurichStefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&AFlorian Jung, LL.M., Senior Associate, Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AMarquard Christen, LL.M., MAS, Partner, Com­pet­i­tion­Sophia Rovelli, Attorney Trainee, Com­pet­i­tion­Nad­ine Anwander, Attorney Trainee, CompetitionDr Matthias Kuert, LL.M., Partner, Capital MarketsMark Cagienard, LL.M. VAT, Partner, TaxChristian Gersbach, LL.M., Partner, EmploymentDirk Spacek, LL.M., Partner, IT/IPCMS ParisAlexandra Rohmert, Partner, Corporate/M&AVincent Desbenoit, Associate, Corporate/M&ACaroline Froger-Michon, Partner, Em­ploy­ment­Ca­mille Baumgarten, Associate, Em­ploy­ment­Aliénor Fevre, Counsel, CommercialManon Fleury, Associate, Com­mer­cialJean-Hugues de la Berge, Partner, TaxWilliam Hamon, Partner, TaxCMS FrankfurtDr Heike Wagner, Partner, Corporate/M&ADr Tobias Kilian, Of Counsel, Corporate/M&ADr Reiner Thieme, Associate, Corporate/M&ACMS HamburgDr Heike Wagner, Partner, Corporate/M&A

Bruker Corporation, a NASDAQ-listed US tech company, entered into a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. The Chemspeed acquisition accelerates Bruker’s entry into lab automation, digitalisation and scientific software solutions. Chemspeed offers modular automation to enhance productivity in R&D and QC departments to achieve more in less time and without additional staff. Chemspeed complements Bruker’s vendor-agnostic plat­form SciY™ for software automation and digital transformation of R&D labs in the life science, biopharma and cleantech industries. An international CMS team headed by Stefan Brunnschweiler and Andrea Relly (Switzerland), in collaboration with the US law firm Nixon Peabody LLP advised Bruker on all legal aspects of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Lead Partner, Corporate / M&AAndrea Relly, Counsel, Corporate / M&ASamuel Gang, Senior Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&AMarquard Christen, Partner, Competition and ComplianceJulia Haas, Senior Associate, Competition and Com­pli­ance­Bernhard Lötscher, Partner, ComplianceSophie Weber, Associate, ComplianceDr Dirk Spacek, Partner, Intellectual PropertyDr Simone Brauch­bar-Birkhäuser, Partner, Intellectual PropertyOlivia Zingg, Associate, Intellectual PropertyMark Cagienard, Partner, TaxJens Lehmann, Senior Associate, TaxMiryam Meile, Senior Associate, Em­ploy­mentSibylle Schnyder, Partner, Real EstateReto Hunsperger, Partner, Com­mer­cialAl­ex­an­der Salamon, Attorney Trainee, Corporate / M&ASophia Rovelli, Attorney Trainee, Corporate / M&AElisabeth Suter, Attorney Trainee, ComplianceCMS BelgiumKai Neuhaus, Partner, Brussel, CompetitionDavid Rappenglück, Associate, Brussel, CompetitionCMS UKRussel Hoare, Partner, Lon­don, Com­pet­i­tion­Claire Barraclough, Associate, Competition

On 31 October 2023, Renais­sance, to­geth­er with industry expert Daniel Lippuner and the management of Heberlein AG, acquired the entire business operations of Heberlein AG. The acquired business will continue to operate unchanged at its current location in Wattwil with the existing management and all employees under the name Heberlein Technology AG. Heberlein was founded in 1835 and has established itself as a leading provider of nozzles for synthetic continuous yarns worldwide, developing, manufacturing, and distributing key components for the chemical fiber industry, with approximately 80 employees. Renais­sance, based in Lausanne, was founded by pension funds for pension funds and has been investing in unlisted Swiss SMEs for over 20 years.A team from CMS, led by Alain Raemy, provided comprehensive legal and tax advice to Renaissance in this transaction. CMS SwitzerlandAlain Raemy, Partner, Corporate / M&AAndrea Relly, Counsel, Corporate / M&AMark Cagienard, Partner, TaxDominik Penkov, Associate, Tax Dr. Simone Brauchbar Birkhäuser, Partner, IP / ITPhilipp Dickenmann, Partner, Dispute ResolutionReto Hunsperger, Partner, RestructuringDr. Marjolaine Jakob, Partner, Re­struc­turin­gOlivia Zingg, Associate, IP / ITHelena Loretan, Associate, Real EstateKatja Bertsche, Senior Associate, Real EstateDr. Miryam Meile, Senior Associate, Employment Anna Mast, Associate, Corporate / M&AAlexander Salamon, Lawyer Trainee, Corporate / M&A

Bruker Corporation, a NASDAQ-listed US tech company, has acquired a majority stake in MIRO Analytical AG, an innovative provider of fast, compact Quantum Cascade Laser (QCL)-based multi-gas analyzers for simultaneous, highest-pre­ci­sion monitoring of up to 10 trace gases. Based near Zürich, the Swiss start-up company MIRO serves atmospheric research and industrial customers, enabling fast, mobile, highest-pre­ci­sion air pollution and greenhouse gas (GHG) analysis to advance climate science, air pollution and industrial process monitoring. MIRO complements the Bruker Optics gas-analysis spectroscopy portfolio with fast, compact, highest-pre­ci­sion QCL multi-trace gas analyzers. An international CMS team headed by Stefan Brunnschweiler and Andrea Relly (Switzerland) as well as Dr Hendrik Hirsch and Berrit Roth-Mingram (Germany) advised Bruker on all legal aspects of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Lead Partner, Corporate / M&AAndrea Relly, Counsel, Corporate / M&AMark Cagienard, Partner, TaxMiryam Meile, Senior Associate, EmploymentAnna Mast, Associate, Corporate / M&AAlexander Salamon, Junior Associate, Corporate / M&ACMS Ger­manyDr Hendrik Hirsch, Lead Partner, Frankfurt/Main, Corporate/M&ADr Berrit Roth-Mingram, Counsel, Frankfurt/Main, Corporate/M&ADr Thomas Hirse, Partner, Dus­sel­dorf, In­tel­lec­tu­al PropertySven Krause, Senior Associate, Dusseldorf, Intellectual Property

Zurich, September 2023 | A team of CMS Switzerland under the lead of Partner Stefan Brunnschweiler and Senior Associate Samuel Felix Gang provided comprehensive advice to FLACHGLAS Wernberg GmbH on all legal aspects regarding the sale of Flachglas (Schweiz) AG, a leading Swiss supplier of high-quality processed glass products for the construction industry, to HSBH Holding AG. The Flachglas Schweiz Group operates at two locations in Wikon (Canton Lucerne) and Gwatt near Thun (Canton Bern). The Flachglas Schweiz Group offers a wide range of glass solutions for the construction of new buildings and the renovation of existing buildings, in particular fire protection glass. For almost four decades now, the group with its approximately 200 employees has been a reliable partner for high-quality glass applications and is known for the quality of its products and services. The FLACHGLAS Wernberg Group has 85 years of experience in the field of glass finishing and produces special glass at three locations in Germany, such as: railway glass, construction glass, showers and many other applications. The three locations in Germany employ approximately 800 people. The sale of the Flachglas Schweiz Group enables the FLACHGLAS Wernberg Group to realise its strategic goals in order to strengthen, modernise and position the three remaining locations well for the future. The parties have agreed not to disclose the purchase price of the transaction. CMS Switzer­land­Stefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&A

Saint-Gobain, a leader in light and sustainable construction, has signed a binding agreement for the sale of its glass processing business Glassolutions in Switzerland to the privately owned German group AEQUITA. CMS Switzerland acted as legal advisor and EY acted as M&A, tax and carve-out advisor to Saint-Gobain. The sale of this division, expected to close by the end of May 2023, is part of Saint-Gobain's ongoing strategic plan to optimize its business profile. The CMS team led by partner Alain Raemy provided comprehensive legal advice to Saint-Gobain on the spin-off of the Glassolutions division and on the sales transaction. CMS TeamAlain Raemy, Partner, Corporate/M&AMark Cagienard, Partner, TaxChristian Gersbach, Partner, EmploymentDr Sibylle Schnyder, Partner, Real EstateTanja Schaub, Counsel, TaxAndrea Relly, Senior Associate, Corporate/M&AThomas Zweifel, Senior Associate, Real EstateHelena Loretan, Associate, Real EstateAnna Mast, Associate, Corporate/M&ARafael Gruber, Attorney Trainee, Real EstateAlexander Salamon, Attorney Trainee, Corporate/M&ANatalie Németh, Corporate Administration

17/02/2023Frank­furt/Main - Fund advised by DPE Deutsche Private Equity, an independent German private equity firm with total assets under management of approximately three billion euros, and VTU Management have sold VTU Group, based in Graz, Austria, to Altor Funds. VTU is a leading provider of engineering solutions in Europe, primarily for the life science industry and in the field of green transition, and has long-standing relationships with numerous global pharmaceutical companies. With approximately 1,200 employees, the VTU Group specialises in end-to-end engineering offerings and covers the entire EPCM(V) value chain (Engineering, Procurement, Construction Management and Validation) together with other value-added services such as green engineering, digitalisation and strategy consulting. Altor Funds, which invests in mid-sized companies with the aim of creating value through growth initiatives and operational improvements, prevailed in a bidding process. The transaction is subject to customary approvals from competent authorities. The parties have agreed not to disclose further details of the transaction. An international CMS team led by lead partner Dr Hendrik Hirsch advised DPE on all trans­ac­tion-re­lated aspects of the sale. The team included lawyers from Germany, Austria, Switzerland, Italy, Belgium and Poland. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate/M&AAnna Mast, Associate, Corporate/M&A CMS Ger­manyDr Hendrik Hirsch, Partner, Frankfurt/Main, Corporate/M&ADr Dirk Baukholt, Principal Counsel, Frankfurt/Main, Corporate/M&AMaxine Notstain, Senior Associate, Frankfurt/Main, Corporate/M&ADr Maximilian Stark, Associate, Frankfurt/Main, Corporate/M&ADr Thomas Hirse, Partner, Düsseldorf, IPSven Krause, Senior Associate, Düsseldorf, IPTina Karakurt, Counsel, Frank­furt/Main, Real Estate & PublicJuliana Kettel, Senior Associate, Frank­furt/Main, Real Estate & PublicStefan Lehr, Partner, Frankfurt/Main, Competition & EUDr Martin Friedberg, Partner, Düsseldorf, TaxDr Markus Pfaff, Partner, Frank­furt/Main, Bank­ing & FinanceThomas Schaak, Senior Associate, Frankfurt/Main, Banking & FinanceCMS Smart Op­er­a­tions-Team­CMS AustriaAlexander Rakosi, Partner, Corporate/M&AFlorian Mayer, Senior Associate, Corporate/M&AMarco Selenic, Senior Associate, Corporate/M&AChristoph Birner, Associate, Corporate/M&AJens Winter, Part­ner, Em­ploy­ment­Shi­ma Babanzadeh, As­so­ci­ate, Em­ploy­ment­Di­eter Zandler, Partner, Com­pet­i­tion­Mar­i­ella Kapoun, Senior As­so­ci­ate, Prop­erty & Pro­cure­ment­Max­imili­an Uidl, Associate, Property & Pro­cure­ment­Mar­lene Wim­mer-Nistel­ber­ger, Senior Associate, Public LawThomas Aspalter, Senior Associate, Tax CMS PolandBlazej Zagorski, Partner, Corporate/M&A Dr Magdalena Zmyslowska, Senior Associate, Corporate/M&A CMS ItalyDaniela Murer, Partner, Corporate/M&AAlessandra Cuni, Counsel, Corporate/M&ACMS BrusselsArnaud Van Oekel, Partner, Corporate/M&A Ségolène Regout, Associate, Corporate/M&A CMS RomaniaRodica Manea, Partner, Corporate/M&A Simona Strava, Associate, Corporate/M&A

Vista Klinik Holding AG, domiciled in Binningen (Switzerland), integrated Augenzentrum Thun AG into its network on 11 January 2023 and is now present in the region of Bernese Oberland. Augenzentrum Thun, which was founded in 2012, specialises in ambulatory eye surgery and offers affiliated doctors the opportunity to provide their patients with first-class care in a professional environment. It is considered the largest ophthalmology service provider in the region. Founded over 30 years ago, Vista Augenpraxen & Kliniken has become a leading centre of excellence for ophthalmology in Switzerland. With its numerous locations, Vista has a broad network of eye clinics and eye practices. At all sites, specialised ophthalmologists offer all treatments and surgical interventions relating to the eye. In this way, Vista guarantees comprehensive and lifelong care for its patients. Forward-looking research activities and the continuous training of all employees ensure quality and sustainability at all sites.A team of CMS Switzerland, led by Stefan Brunnschweiler and Franziska Hammer, advised Vista Augenpraxen & Kliniken on all legal matters of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate / M&AFranziska Hammer, Counsel, Corporate / M&A  Anna Mast, Associate, Corporate / M&ADr Miryam Meile, Associate, Em­ploy­ment­Premton Haziri, Attorney Trainee

Lab14 GmbH, a portfolio company of RSBG SE, the investment company of the RAG-Foundation, acquires a majority stake in Liestal-based Nanosurf AG. Zurich, 26 January 2023 

The Swiss investor Capvis, which specialises in medium-sized investments, acquires a majority stake in the Lucerne-based SCHURTER Group. The founding and previous owner family continues to hold a stake in the company and is represented on the board of directors by Thomas Schurter.

Zurich, 4 January 2023 Bruker Corporation, a NASDAQ-listed US tech company, has entered into a partnership with Swiss firm Biognosys AG to deliver advanced proteomics CRO services for US biopharma and biomarker customers. As part of the partnership, Bruker has made a ma­jor­ity-own­er­ship investment in Biognosys AG. Biognosys is a leader in the development of proteomics technologies and solutions for pharmaceutical and biotech research. The strategic partnership is expected to create unique synergies between Biognosys’ portfolio of proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the US. Details of the transaction were not disclosed. An international CMS team headed by Stefan Brunnschweiler and Dr Hendrik Hirsch advised Bruker on all legal aspects of the transaction. Bruker has also relied on the expertise of CMS in the past. Previous work by CMS for Bruker Corporation included providing legal advice on the company’s investment in PreOmics. CMS Switzer­land­Stefan Brunnschweiler, Lead Partner, Zurich, Corporate / M&AAndrea Relly, Senior Associate, Corporate / M&ASamuel Felix Gang, Senior Associate, Corporate / M&APascal Stocker, Senior Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&ADr Simone Brauchbar Birkhäuser, Partner, Intellectual PropertyMark Cagienard, Partner, TaxSarah Keller, Senior Associate, Employment & PensionsHadi Mirzai, Senior Associate, Life Sciences and Com­pet­i­tion­Valentina Balaj, As­so­ci­ate, Reg­u­lat­ory / ComplianceCMS Ger­manyDr Hendrik Hirsch, Lead Partner, Frankfurt/Main, Corporate/M&ADr Berrit Roth-Mingram, Senior Associate, Frankfurt/Main, Corporate/M&ADr Thomas Hirse, Partner, Dus­sel­dorf, In­tel­lec­tu­al PropertySven Krause, Senior Associate, Dusseldorf, Intellectual Property

Zurich, 28 October 2022The Voigt Group and PHOENIX Pharma Switzerland have agreed to merge their subsidiaries, each active in pharmaceutical logistics and pharmaceutical wholesale sectors respectively, into a 50/50 joint venture. The two long-established and financially sound companies are an ideal fit with complementary offerings and competencies in the supply chain. Subject to approval by the Swiss Competition Commission, this joint venture will create a new, competent and sustainable player in the supply chain of the Swiss healthcare market.A CMS Switzerland team led by Dr Patrick Sommer provided comprehensive legal advice to Voigt Group on this joint venture. CMS Switzerland: Dr. Patrick Sommer, Partner, Lead, Corporate / M&A, Competition & EUAlain Raemy, Partner, Corporate / M&AMarquard Christen, Partner, Competition & EUDirk Spacek, Partner, Intellectual PropertyDr Simone Brauchbar Birkhäuser, Counsel, Intellectual PropertyHadi Mirzai, Associate, Life Sciences, Competition & EUAlexandra Stocker, Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&ADr. Matthias Kuert, Associate, Banking & FinanceThomas Zweifel, Associate, Real EstateChristina Winter, Associate, Employment